Author Interviews, Dermatology, Kidney Disease / 22.06.2020

MedicalResearch.com Interview with: Gil Yosipovitch, MD, Professor Miami Itch Center Lennar Medical Foundation South Miami Clinic in Coral Gables University of Miami Health System MedicalResearch.com: What is the background for this study? Response: Chronic Pruritus is a common and burdensome condition in patients with end stage chronic kidney disease (CKD). It is Present at all stages of CKD, not only in patients undergoing hemodialysis (including stage 3-5 CKD). There are no approved treatments for this condition in US and Europe. CKD pruritus   has significant impact on quality of life of patients with higher mortality rates due to its effect on sleep. Studies in the last 2 decades have shown that in patients with CKD pruritus there is an imbalance between endogenous mu opioids that are over expressed to Kappa Opioids that are down regulated.   Difelikefalin (DFK) is a novel peripherally selective kappa opioid receptor (KOR) agonist.   Study of IV DFK administration  in hemodialysis patients has  recently  been published and showed significant anti Pruritic effect ( NEJM Fishbane et al. 382: 289-290, 2020). (more…)
Author Interviews, Dermatology, Melanoma, Technology / 17.06.2020

MedicalResearch.com Interview with: Chi Hwan Lee PhD Assistant Professor of Biomedical Engineering and Mechanical Engineering, and by Courtesy, of Materials Engineering, and Speech, Language, & Hearing Sciences Purdue University  MedicalResearch.com: What is the background for this study? Response: Conventional melanoma therapiesincluding chemotherapy and radiotherapy, suffer from the toxicity and side effects of repeated treatments due to the aggressive and recurrent nature of melanoma cells. Less-invasive topical chemotherapies by utilizing miniaturized polymeric microneedles are emerged as an alternative, but the sustained, long-lasting release of drug cargos remains challenged due to the rapidly dissolving behavior of polymers (typically, within 15 min-2 hrs). In addition, the size of the microneedles is still large for small, curvilinear and sensitive areas of tissues such as cornea (for ocular melanoma). (more…)
Author Interviews, Dermatology, Pediatrics, Pharmaceutical Companies, Regeneron / 15.06.2020

MedicalResearch.com Interview with: Amy S Paller, MD Chair, Department of Dermatology Director, Skin Biology and Diseases Resource-Based Center Walter J. Hamlin Professor of Dermatology Professor of Dermatology and Pediatrics (Dermatology) Feinberg School of Medicine Northwestern University  Dr. Paller discusses the FDA approval of Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis (eczema), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.  MedicalResearch.com: What is the background for this announcement? Would you briefly discuss what is meant by atopic dermatitis and how it affects children? Response: “Atopic dermatitis, the most common form of eczema, is a chronic inflammatory disease that often appears as a rash on the skin. Moderate-to-severe atopic dermatitis is characterized by rashes that can potentially cover much of the body and can include intense, persistent itching, skin lesions and skin dryness, cracking, redness or darkness, crusting and oozing. Itch is one of the most burdensome symptoms for patients and can be debilitating. This recent FDA approval expands the use of Dupilumab in the U.S. to include children aged 6 to 11 years with uncontrolled moderate-to-severe atopic dermatitis, making it the only biologic medicine approved for this use in this population. Dupilumab is also approved in the U.S. to treat patients aged 12 years and older with moderate-to-severe atopic dermatitis. Moderate-to-severe atopic dermatitis can place a particularly substantial burden on young children aged 6 to 11 years and their families. Limited treatment options leave many of these children to cope with intense, unrelenting itch and skin lesions. Families of these children can spend countless hours helping them to manage their disease.” (more…)
Author Interviews, Dermatology / 12.06.2020

MedicalResearch.com Interview with: David Granville PhD, FAHA Professor, Pathology and Laboratory Medicine, UBC Associate Director, Vancouver Coastal Health Research Institute, VGH-UBC Associate Director, BC Professional Firefighters Burn & Wound Healing Group, Department of Surgery, UBC Principal Investigator, iCORD and UBC Centre for Heart Lung Innovation MedicalResearch.com: What is the background for this study? Response: Atopic dermatitis (aka. eczema) is a chronic inflammatory skin condition characterized by patches of dry, red, itchy skin. These patches can come and go - a process often referred to as 'flare ups'. Often when these flare ups occur, people avoid going out, or to work, resulting in lost productivity and reduced quality of life. While the cause of these flare-ups is not completely understood, a loss of the skin's protective barrier function is believed to be a triggering event. This is because the outer layer of skin (epidermis) acts as a barrier to allergens and other foreign entities from getting into the skin. When this outer barrier is lost, allergens are able to cross and penetrate the deeper layers of skin. This triggers an inflammatory response. The inflammatory response, in turn, can release factors that cause further disruption of the barrier thereby exacerbating the flare up. The outer skin barrier can be thought of in terms of a brick wall in which the 'bricks', or skin cells in this case, are held together by a molecular 'grout' known as adhesion proteins. If these adhesion proteins, which tightly anchor the skin cells together, are lost, the skin becomes more permeable to the outer environment, allowing foreign antigens to enter in, and conversely, moisture to escape out resulting in skin dryness and shedding (more…)
Author Interviews, Dermatology, Stem Cells, Surgical Research / 01.06.2020

MedicalResearch.com Interview with: Charles-de-SáM.D., Ph.D. Rio de Janeiro, Brazil MedicalResearch.com: What is the background for this study? Response: Our clinical trial was based on our clinical skin observations in areas submitted to a lipotransfer previously, an ordinary practice in plastic surgery. These clinical observations lead us to investigate what will be the key element played in these findings. Our scientific support investigation addressed the Dardick1and Zuk, P2 studies, that demonstrated fibroblastic-like cells in adipose tissue with regenerative ability. Our clinical trial proposal is to investigate the adipose-derived stem cell (ADSC) role in the photoaged skin. The direct endpoint of the study was to assess the histological benefits provided by the subdermal ADSC injection. Mesenchymal stem cells were obtained from lipoaspirates, expanded in vitro, and introduced into the facial skin of 20 patients submitted after three to four months to a face-lifting surgery. In the retrieved skin, immunocytochemical and ultrastructural analysis quantified elastic matrix components, cathepsin-K, metalloprotease MMP-12, and the macrophage M2 markers: CD68, CD206 and heme-oxygenase-1.An overview of the trial steps is described in the infographic.  (more…)
Author Interviews, Dermatology, Genetic Research / 01.06.2020

MedicalResearch.com Interview with: Sarah E. Millar, Ph.D. Director, Black Family Stem Cell Institute Professor, Departments of Cell, Developmental and Regenerative Biology and Dermatology Icahn School of Medicine at Mount Sinai New York, NY MedicalResearch.com: What is the background for this study? Response: One of the major roles of the skin is to serve as a protective barrier, both preventing external insults, such as toxins and pathogens, from entering the body, and helping to retain moisture. The mechanisms required for appropriate skin barrier formation remain incompletely understood. Elucidating these processes is important for understanding and developing improved treatments for dermatological diseases in which the skin barrier is dysfunctional, such as eczema and psoriasis. Understanding epigenetic regulators, proteins that modify the structure of genetic material, is an area of scientific interest, as many new drugs target these proteins. Importantly, multiple epigenetic regulators have been shown to be important in skin development. My lab has focused on one group of epigenetic regulators, histone deacetylases (HDACs), because HDAC inhibitors show promise for treating several different cancers and other disorders in which cell proliferation is poorly controlled. We previously showed that HDACs 1 and 2 are required for normal skin development. In the current study, we investigated whether the related protein HDAC3 is also important in establishing the skin barrier.  (more…)
Author Interviews, Dermatology / 21.05.2020

MedicalResearch.com Interview with: Dr. Melanie D. Palm, MD, MBA Board-certified dermatologist and cosmetic surgeon San Diego, CA Clinical investigator in the Restylane Kysse phase 3 Galaderma trial Dr. Palm discusses the recent announcement that the FDA has approved Restylane® Kysse for lip augmentation and the correction of upper perioral rhytids (wrinkles)  in adults over the age of 21.   MedicalResearch.com: What is the background for this announcement?
    • Restylane® Kysse has been approved and used in Europe and Canada for several years. It is now the first FDA-approved hyaluronic acid (HA) lip filler in the U.S. formulated with XpresHAn Technology™ (pronounced ex-'spre-shan’) for smooth, natural-looking results.
    • It is FDA-approved for use not only in the lip but for improvement of upper lip lines.
    • Restylane Kysse is the third product (following Restylane Defyne and Restylane Refyne) in the Restylane family of fillers to use XpresHAn Technology™ which allows for a gel that integrates into the skin for natural expression in motion
(more…)
Author Interviews, Dermatology / 13.05.2020

MedicalResearch.com Interview with: Brian S. Kim, MD, MTR, FAAD Associate Professor of Medicine (Dermatology) Co-Director, Center for the Study of Itch and Sensory Disorders Division of Dermatology, Department of Medicine Washington University School of Medicine St. Louis, MO  MedicalResearch.com: What is the background for this study? What are the main findings? Response: Itch is the central and most debilitating symptom of atopic dermatitis. However, surprisingly, measuring itch or quality of life in clinical trials is not often a primary endpoint. Therefore, this study focuses in very detailed fashion on how ruxolitinib cream improves pruritus in a clinically meaningful way and its ultimate impact on quality of life. What patients want to know at the end of the day is how much will this drug change my life?  Not, whether it statistically beat out a placebo group. Indeed, what this study shows is that ruxolitinib cream has a major impact on itch in a meaningful way that is also tied to improvements in quality of life. (more…)
Author Interviews, Dermatology, Melanoma / 08.05.2020

MedicalResearch.com Interview with: Neelam A. Vashi, MD Associate Professor of Dermatology Director, Boston University Center for Ethnic Skin Director, Cosmetic and Laser Center Boston University School of Medicine and Daniela P.Sanchez BS Boston Medical Center Boston, MA 02118 MedicalResearch.com: What is the background for this study? Response: Although melanoma most commonly affects Caucasians, Hispanics are disproportionately affected by greater morbidity and mortality rates when diagnosed. Poor prognosis in Hispanic patients is likely multifactorial, and may be secondary to lack of knowledge or misconceptions about melanoma risk, atypical presentation, impaired access to care, and language barriers, ultimately resulting in a delay in diagnosis. (more…)
Author Interviews, Dermatology, Neurology / 28.04.2020

MedicalResearch.com Interview with: Santosh K. Mishra M.Tech., PhD Assistant Professor of Neuroscience Department of Molecular Biomedical Sciences NC State Veterinary Medicine Raleigh, NC 2760 MedicalResearch.com: What is the background for this study? Would you briefly explain what is meant by atopic dermatitis? Response: Chronic allergic itch is a worldwide problem that leads to substantial health expenses,but what causes this universal urge to scratch remains elusive in chronic allergic itch. Atopic dermatitis is a common allergic skin disease that often associated with extremely itchy and inflamed skin. In our study, we showed, for the first time, a molecular pathway that is involved in chronic allergic itch as we identified an endogenous mediator (periostin) and a new role for its sensory neuron receptor, the integrin αVβ3, which drives the excitability and transmission of itch signal to the spinal cord.  (more…)
Author Interviews, COVID -19 Coronavirus, Dermatology / 04.04.2020

MedicalResearch.com Interview with: Amit Gefen PhD Professor of Biomedical Engineering The Herbert J. Berman Chair in Vascular Bioengineering Department of Biomedical Engineering, Faculty of Engineering Tel Aviv University, Tel Aviv, Israel MedicalResearch.com: What is the background for this study? Response: Although we are witnessing continuous progress in medical technologies, the design of many of the most commonly used medical devices e.g. oxygen masks or cervical collars has changed very little over a period of decades. Not surprisingly, these devices are also the ones which are frequently associated with device-related pressure ulcers (DRPUs). These DRPUs are frequently a hospital-acquired injury which involves risk of infections (including e.g. sepsis and antibiotic-resistant bacteria), scarring with serious psychological consequences, additional and significant healthcare costs and a basis for liability suits and litigation. The problem is massive in Europe and the US and is most frequently encountered in clinical environments where devices are used intensively, such as in operation theatres, intensive care units and emergency care settings (in both adult and pediatric medicine), but also, in elderly care facilities where patients often have fragile skin. With the current pandemic spread of the coronavirus, facilities worldwide are experiencing a considerable rise in usage of emergency and intensive care equipment, which will very likely considerably escalate the incidence of DRPUs. Early in 2019, a committee of global experts which I have chaired, has met for two days of intensive deliberation in London UK, to start developing the first-ever international consensus document on device-related pressure ulcers . After a rigorous review process by an international review committee of other experts, this consensus report has been published as a Special Edition of the Journal of Wound Care in February 2019 (https://doi.org/10.12968/jowc.2020.29.Sup2a.S1), under the name "Device-related pressure ulcers: SECURE prevention". The publisher has kindly made this publication freely downloadable and thereby accessible and available to anyone, including all professionals who may need guidance in this regard, including clinicians, industry, regulators and academic researches. (more…)
Author Interviews, Dermatology, Technology / 03.04.2020

MedicalResearch.com Interview with: Jung-Im Na, MD PhD Associate Professor, Department of Dermatology Seoul National University Bundang Hospital Korea  MedicalResearch.com: What is the background for this study? Would you briefly explain what is meant by a convolutional neural network? Response: When a very young child looks at a picture, she can easily identify cats and dogs, however, even the most advanced computers had struggled at this task until recently. Computers began to “see” with the recent advancement of Deep Learning techniques. Deep Learning is a machine learning technique that teaches computers to learn from raw data. Most deep learning methods use artificial neural network architectures, imitating human brain, and convolutional neural networks (CNN) is a particular type of deep learning architecture, imitating the visual cortex. CNN is especially powerful for recognizing images. CNN exploit the information contained in image datasets to automatically learn features and patterns. (more…)
Allergies, Author Interviews, Dermatology / 20.03.2020

MedicalResearch.com Interview with: Gil Yosipovitch, MD, Professor Miami Itch Center Lennar Medical Foundation South Miami Clinic in Coral Gables University of Miami Health System MedicalResearch.com: What is the background for this study? How does Dupilumab (Dupixent) differ from other medications for atopic dermatitis/eczema? Response: Atopic dermatitis (AD) is characterized by intense itch (pruritus) that is one of the most burdensome symptoms; therefore, rapid and sustained improvement in itch is an important marker of treatment benefit. Dupixent® (dupilumab) is approved in the U.S. for adults and adolescents with inadequately-controlled moderate-to-severe Atopic Dermatitis. Dupilumab remains the first and only biologic medicine for uncontrolled moderate-to-severe atopic dermatitis. Dupilumab is the first and only fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. Data from dupilumab clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps.  (more…)
Author Interviews, Dermatology, Pediatrics / 18.03.2020

MedicalResearch.com Interview with: Adawiyah Jamil, AdvMDerm Associate Professor at Department of Medicine University Kebangsaan Malaysia Medical Center Kuala Lumpur, Malaysia MedicalResearch.com: What is the background for this study? Response: We commonly observed poor dietary pattern and multiple food restrictions imposed on atopic dermatitis (AD) children by their parents in our daily clinical practice. Food allergy is often associated with AD, however excessive and medically unsubstantiated restriction may lead to various health issues. AD is a chronic skin disease, like any other chronic diseases it affects an individual’s general health. Growth and development are key measures of health in children. We embarked on this study as we were very worried of the consequences of medically unsupervised food restriction, especially those with severe disease.  We were concerned about how our atopic dermatitis children are eating and how to help them. (more…)
Allergies, Asthma, Author Interviews, Dermatology, Pediatrics / 10.03.2020

MedicalResearch.com Interview with: Marcella Aquino, M.D. Hasbro Children's Hospital Department of Pediatrics Division of Allergy & Immunology Associate Professor of Pediatrics   Daphne Koinis-Mitchell PhD Professor (Research) in the Departments of Psychiatry and Human Behavior and Pediatrics Warren Alpert Medical School of Brown University Providence, Rhode Island 02903   MedicalResearch.com: What is the background for this study? Response: Urban minority children with asthma are at increased risk for sleep loss and poorer sleep quality secondary to socio-contextual stressors (poverty, stressors of urban living) and the underlying challenges related to following possibly complex asthma treatment regimens. Atopic dermatitis (AD) is very frequently seen in children with asthma and increases the risk for poor quality sleep, for example difficulty falling asleep, awakenings during the night, difficulty awakening in the morning, and/or daytime sleepiness.  (more…)
Author Interviews, Dermatology, Immunotherapy, Science / 27.02.2020

MedicalResearch.com Interview with: Brian S. Kim, MD, MTR, FAAD Associate Professor of Medicine (Dermatology) Co-Director, Center for the Study of Itch and Sensory Disorders Division of Dermatology, Department of Medicine Washington University School of Medicine St. Louis, MO 63110 MedicalResearch.com: What is the background for this study? Response: It has been known well for decades that a specific part of your immune system called the “type 2 immune response” is overactive in atopic disease. Indeed, that is what new drugs like dupilumab block so effectively and thus revolutionized the treatment of atopic disorders just in the last few years. In fact, our lab focuses predominantly on this part of the immune system. However, increasingly it is becoming recognized that the immune system is not just about whether it is “on or off” but rather a balance like yin and yang. Along these lines, we noticed that a cell that could theoretically counterbalance atopic inflammation was significantly deficient in many patients with eczema. This cell is the natural killer (NK) cell. (more…)
Author Interviews, Cancer Research, Dermatology, JAMA / 19.02.2020

MedicalResearch.com Interview with: Nikolai Dyrberg Loft MD, Ph.D.-fellow Department of Dermatology and Allergy Gentofte Hospital Hellerup MedicalResearch.com: What is the background for this study? Response: Epidemiological studies examining the association between psoriasis or psoriatic arthritis and cancer have reported conflicting results. Some studies report an increased risk of cancer in individuals with psoriasis or psoriatic arthritis and others do not. Whether individuals with psoriasis or psoriatic arthritis have an increased risk of cancer is important as this might help guiding in clinical practice. In order to determine if there is an increased risk of cancer and the magnitude of this risk, a systematic review of the literature and meta-analysis is needed.  (more…)
Author Interviews, BMJ, Dermatology, Technology / 13.02.2020

MedicalResearch.com Interview with: Professor Jon Deeks PhD, CStat Institute of Applied Health Research Professor of Biostatistics College of Medical and Dental Sciences University of Birmingham, UK MedicalResearch.com: What is the background for this study? Response: Skin cancer is one of the most common cancers in the world, and the incidence is increasing. In 2003, the World Health Organization estimated that between two and three million skin cancers occur globally each year, 80% of which are basal cell carcinoma, 16% cutaneous squamous cell carcinoma, and 4% melanoma. The potential for melanoma to metastasise to other parts of the body means that it is responsible for up to 75% of skin cancer deaths. Five year survival can be as high as 91-95% for melanoma if it is identified early, which makes early detection and treatment key to improving survival. Early detection of melanoma is reliant on people with new or changing moles seeking early advice from medical professionals. Skin cancer smartphone applications (“apps”) provide a technological approach to assist people with suspicious lesions to decide whether they should seek further medical attention. Of increasing interest are smartphone apps that use inbuilt algorithms (or “artificial intelligence”) that catalogue and classify images of lesions into high or low risk for skin cancer (usually melanoma). Apps with inbuilt algorithms that make a medical claim are now classified as medical devices that require regulatory approval. These apps could be harmful if recommendations are erroneous, particularly if false reassurance leads to delays in people obtaining medical assessment.  CE (Conformit Europenne) marking has been applied to allow distribution of two algorithm based apps in Europe (SkinScan and SkinVision), one of which is also available in Australia and New Zealand. However, no apps currently have United States Food and Drug Administration (FDA) approval to allow their distribution in the US and Canada. We have completed a systematic review of studies that examine the accuracy of all apps that use inbuilt algorithms to identify skin cancer in users of smartphones.  We report on the scope, findings, and validity of the evidence. (more…)
Author Interviews, Brigham & Women's - Harvard, Dermatology, Gender Differences, JAMA, Melanoma / 12.02.2020

MedicalResearch.com Interview with: Arash Mostaghimi, MD, MPA, MPH Director, Inpatient Dermatology , Brigham and Women's Hospital Instructor, Harvard Medical School Department of Dermatology Brigham and Women's Hospital MedicalResearch.com: What is the background for this study? What are the main findings?  Response: Smaller studies have demonstrated increased risk for skin cancer among gay men.  Prior to this study this data had not been confirmed in a nationally representative database. (more…)
Author Interviews, Dermatology, Environmental Risks, JAMA / 22.01.2020

Comments from the FDA on this JAMA Dermatology study: Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial  Sunscreen CDC Phil imageMedicalResearch.com: What is the background for this study? Response: A prior pilot study published in JAMA in May 2019 demonstrated the systemic absorption of 4 sunscreen active ingredients; additional studies are needed to determine the systemic absorption of additional active ingredients, and how quickly absorption occurs.  This study assessed the systemic absorption of the 6 active ingredients (avobenzone, oxybenzone, octocrylene, homosalate, octisalate and octinoxate) in 4 sunscreen products under single and maximal-use conditions.  (more…)
Author Interviews, Depression, Dermatology, Pediatrics / 21.01.2020

MedicalResearch.com Interview with: Dr. Jonathan L. Silverberg MD PhD MPH Director of Clinical Research and Contact Dermatitis Associate Professor of Dermatology George Washington University School of Medicine and Health Sciences Washington, DC  MedicalResearch.com: What is the background for this study? Response: We previously found that children from single parent families, and unsafe or unsupportive neighborhoods are more likely to have atopic dermatitis. Parents in these settings may experience greater psychosocial distress and higher rates of depression in the post-partum period and beyond. As such, we sought to understand the relationship of maternal depression with atopic dermatitis in their children. (more…)
Author Interviews, Dermatology, Mental Health Research, Pediatrics / 15.01.2020

MedicalResearch.com Interview with: Lucia Diaz, M.D., is chief of pediatric dermatology, dermatology residency associate program director and assistant professor of medicine and pediatrics at Dell Medical School. She is also co-director of the dermatology-rheumatology combined clinic at Dell Children’s Medical Center. Sasha Jaquez, Ph.D. is a pediatric psychologist at Dell Children's Medical School/Dell Children's Medical Center and specializes in seeing children with chronic medical illness, including skin disorders.     MedicalResearch.com: What is the background for this study? Response: Trichotillomania (TTM) can be an extremely disabling chronic condition that impacts the psychosocial development of children. It is classified by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) as an obsessive-compulsive disorder, where a person recurrently pulls out hair from any region of their body resulting in hair loss. Recognizing this disorder and being informed of treatment options allows medical providers to correctly diagnose and intervene early in the disease course. We reviewed the psychosocial impacts of pediatric trichotillomania and the current evidence-based interventions used in the population.  (more…)
Author Interviews, Dermatology, Education, Gender Differences, JAMA, Race/Ethnic Diversity / 08.01.2020

MedicalResearch.com Interview with: Imam Xierali, PhD Associate Professor / UT Southwestern Medical Center Dallas, Texas MedicalResearch.com: What is the background for this study? Response: Despite the continued efforts in academic medicine to increase the representation of women and minorities underrepresented in medicine (URM), there is a lack of information on trends in dermatology department faculty diversity and how they compare with those in other clinical departments. (more…)
Author Interviews, Dermatology, HPV, Infections, JAMA, OBGYNE / 08.01.2020

MedicalResearch.com Interview with: Niklas Worm Andersson, MD Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen NV, Denmark MedicalResearch.com: What is the background for this study? What is Podophyllotoxin used for? Response: Podophyllotoxin is an antimitotic agent primarily used in the local treatment of anogenital warts, which are among the most prevalent sexually transmitted diseases worldwide. Most women affected by anogenital warts are of childbearing age and during pregnancy, they may become symptomatic, enlarge, or multiply. While podophyllotoxin is part of first-line treatment of anogenital warts for the non-pregnant population, it is contraindicated during pregnancy. Fetal safety data are limited and to our knowledge, no previous human data exist to help inform on this issue. (more…)
Author Interviews, Brigham & Women's - Harvard, Dermatology, Science / 05.01.2020

MedicalResearch.com Interview with: Dr. D. Branch Moody, MD Principal Investigator Associate Physician, Brigham and Women's Hospital Professor of Medicine, Harvard Medical School MedicalResearch.com: What is the background for this study? Is the CD1a molecule found on the skin's Langerhans cells? Response: With increasing industrialization worldwide, people apply cosmetics and other consumer products to the skin, leading to contact dermatitis, which is becoming increasingly common. Immunologists know that T cells participate in dermatitis reactions. However, T cells usually recognize and respond to antigens that are peptides rather than the non-peptide antigens that cause contact dermatitis. (more…)
Author Interviews, Dermatology / 20.12.2019

MedicalResearch.com Interview with: Dr Kim Kjoeller MD Executive Vice President, Global Research & Development LEO Pharm Discusses the recent announcement from  LEO Pharma A/S that tralokinumab  met all primary and secondary endpoints in its three Phase 3 studies (ECZTRA 1-3) for the treatment of moderate-to-severe atopic dermatitis in adults. MedicalResearch.com: What is the background for this study? Would you briefly explain what is meant by Atopic Dermatitis? Response: Atopic Dermatitis (AD) – also known as ‘atopic eczema’ – is a chronic, inflammatory, heterogeneous skin disease characterized by intense itch and eczematous lesions is the most common inflammatory skin disease in the world, with limited effective treatment options, especially for moderate-to-severe patients. The primary objective of these studies was to evaluate the efficacy of tralokinumab compared with placebo in treating moderate-to-severe atopic dermatitis.
  • ECZTRA 1 and 2 evaluated the use of tralokinumab as monotherapy
  • ECZTRA 3 evaluated the use of tralokinumab in combination with a topical corticosteroid (TCS).
(more…)
Author Interviews, Cancer Research, Dermatology, JAMA / 11.12.2019

MedicalResearch.com Interview with: Lily Wang Student at University of Toronto Toronto, Ontario, Canada  MedicalResearch.com: What is the background for this study? Response:  Impaired skin barrier and aberrant immune function in atopic dermatitis (AD) may impact immune response to malignancy. Conflicting data exist on the risk of cancer in patients with AD. The purpose of our study was to determine the risk of non-cutaneous and cutaneous cancers in patients with atopic dermatitis compared to the general population (i.e. without AD).  (more…)
Aging, Dermatology, JAMA / 26.11.2019

MedicalResearch.com Interview with: Christian Sell, PhD Associate Professor of Biochemistry and Molecular Biology Drexel University College of Medicine MedicalResearch.com: What is the background for this study? Response: In terms of background, the drug rapamycin targets a pathway that scientists know is critical for growth and development but is also a key regulator of lifespan in many model organisms such as worms, flies, and mice. This pathway is known as the mTOR pathway. Rapamycin is already in use clinically, it is given to people who have received organ transplants to prevent rejection and is also in trials to treat some forms of cancer, at very high doses. Many studies in mice have shown that rapamycin delays aging and prevents age-related disorders such as the decline in heart function and cognitive function. Based on this work, there is a strong expectation that these results will translate into humans, but no studies have been done due to concerns regarding potential side effects of rapamycin when the drug is given orally to prevent rejection. Our previous studies have shown that a very low dose of rapamcyin can reduce the aging of human cells and improve cell growth, while the high does used for organ transplant patients actually block cell growth.  We decided to test the impact of low dose rapamycin on aging in the skin because we could treat people safely. Previous studies have shown that the drug does not get into the blood stream when high doses were given topically to people with a rare genetic disorder, so we knew that the low doses used in our study would not get into the bloodstream and would be safe for the patients. (more…)
Author Interviews, Dermatology, Gender Differences, Pediatrics / 17.11.2019

MedicalResearch.com Interview with: Markus Boos, MD, PhD Member of the Society for Pediatric Dermatology. Attending pediatric dermatologist Seattle Children's Hospital Assistant Professor in the Department of Pediatrics University of Washington School of Medicine  MedicalResearch.com: What is the background for this study? Response: Our understanding of the cutaneous health of sexual and gender minority (SGM) individuals (lesbian, gay, bisexual, transgender, queer, asexual, intersex, nonbinary, etc.) remains nascent. This dearth of understanding of the unique needs of SGM children is even more pronounced. This 2-part review article provides practical advice on how to best engage with young SGM patients and serve the distinct needs of this minority population, with a specific emphasis on dermatologic conditions. (more…)